NCT02105662View on ClinicalTrials.gov

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

June 3, 2014

Primary Completion Date

February 20, 2015

Study Completion Date

May 22, 2015

Conditions
Chronic Hepatitis C
Interventions
DRUG

Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets

MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02105662 - An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061) | Biotech Hunter | Biotech Hunter